To prevent tumor recurrence, HCC patients with CTA expression in TFL could be selected for adjuvant therapy, either by therapeutic targeting of these CTAs, other (immuno-) therapeutic strategies, or a combination of both. This evidence concerns the gene ZC3H12D and hepatocellular carcinoma.